Drug Profile

ASP 0892

Alternative Names: ARA h1,2,3-Lamp-vax peanut vaccine; ARA-LAMP-Vax™; ASP0892; Peanut allergy vaccine - Immunomic

Latest Information Update: 11 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immunomic Therapeutics
Developer Astellas Pharma
Class DNA vaccines; Food allergy immunotherapies
Mechanism of Action Th1 cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Peanut hypersensitivity

Most Recent Events

11 Oct 2021 Astellas Pharma completes a phase I trial in Peanut hypersensitivity (Prevention) (In Adolescents)in USA (Intradermal) (NCT03755713)
30 Jun 2021 Discontinued - Phase-I for Peanut hypersensitivity (In adolescents, Prevention) in USA (Intradermal)
30 Jun 2021 Discontinued - Phase-I for Peanut hypersensitivity (Prevention) in USA (IM)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com